Matches in DBpedia 2015-04 for { <http://dbpedia.org/resource/Secukinumab> ?p ?o }
Showing triples 1 to 51 of
51
with 100 triples per page.
- Secukinumab abstract "Secukinumab (Tradename Cosentyx) is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. It targets member A from the cytokine family of interleukin 17. Novartis Pharma AG, the drug's developer, plans to market it under the trade name "Cosentyx." It is highly specific to the human immunoglobulinG1k (IgG1k) subclass.On January 21, 2015, the United States Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.In July 2014 secukinumab established superiority to placebo and to etanercept for the treatment of chronic plaque psoriasis in Phase III clinical trials. In October 2014, the FDA Dermatologic and Ophthalmic Drugs Advisory Committee unanimously voted to recommend the drug for FDA approval, although this vote in and of itself does not constitute an approval. However, the FDA typically follows recommendations from these committees. In October 2014, Novartis announced that the drug had achieved a primary clinical endpoint in two phase III clinical trials for ankylosing spondylitis. As of 28 October, the relevant FDA committee had not yet responded to these results. In early November 2014, Novartis also released the results of a Phase 3 study on psoriatic arthritis that yielded very promising results.Although the drug was originally intended to treat rheumatoid arthritis, phase II clinical trials for this condition yielded disappointing results. Similarly, while patients in a phase II clinical trial for psoriatic arthritis did show improvement over placebo, the improvement did not meet adequate endpoints and Novartis is considering whether to do more research for this condition. Novartis has said that it is targeting approval and release in early 2015 for plaque psoriasis and ankylosing spondylitis indications. It is also in a phase II clinical trial for Multiple Sclerosis as it has exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS.".
- Secukinumab atcPrefix "L04".
- Secukinumab atcSuffix "AC10".
- Secukinumab drugbank "DB09029".
- Secukinumab wikiPageID "33024133".
- Secukinumab wikiPageRevisionID "645733627".
- Secukinumab atcPrefix "L04".
- Secukinumab atcSuffix "AC10".
- Secukinumab c "6584".
- Secukinumab chemspiderid "NA".
- Secukinumab drugbank "DB09029".
- Secukinumab h "10134".
- Secukinumab hasPhotoCollection Secukinumab.
- Secukinumab legalStatus "Approved".
- Secukinumab mabType "mab".
- Secukinumab molecularWeight "147.94".
- Secukinumab n "1754".
- Secukinumab o "2042".
- Secukinumab s "44".
- Secukinumab source "u".
- Secukinumab synonyms "AIN457".
- Secukinumab target IL17A.
- Secukinumab type "mab".
- Secukinumab verifiedfields "changed".
- Secukinumab verifiedrevid "464388281".
- Secukinumab subject Category:Immunosuppressants.
- Secukinumab subject Category:Novartis.
- Secukinumab type Agent114778436.
- Secukinumab type CausalAgent100007347.
- Secukinumab type Drug103247620.
- Secukinumab type Immunosuppressant103562958.
- Secukinumab type Immunosuppressants.
- Secukinumab type Matter100020827.
- Secukinumab type Medicine103740161.
- Secukinumab type PhysicalEntity100001930.
- Secukinumab type Substance100020090.
- Secukinumab type Drug.
- Secukinumab type Thing.
- Secukinumab type Q8386.
- Secukinumab comment "Secukinumab (Tradename Cosentyx) is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. It targets member A from the cytokine family of interleukin 17.".
- Secukinumab label "Secukinumab".
- Secukinumab label "Secukinumab".
- Secukinumab label "セクキヌマブ".
- Secukinumab sameAs Secukinumab.
- Secukinumab sameAs セクキヌマブ.
- Secukinumab sameAs m.0h560sz.
- Secukinumab sameAs Q7444755.
- Secukinumab sameAs Q7444755.
- Secukinumab sameAs Secukinumab.
- Secukinumab wasDerivedFrom Secukinumab?oldid=645733627.
- Secukinumab isPrimaryTopicOf Secukinumab.